Development of novel treatments for hepatitis C

The Lancet Infectious Diseases

Volumn 9, Issue 2, 2009, Pages 108-117

  Webster, Daniel P ^a   Klenerman, Paul ^b   Collier, Jane ^a   Jeffery, Katie JM ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4' CHLORO 4 (4 HYDROXY 1 PIPERIDINYLCARBONYL)BIPHENYL 2 YLMETHOXY] 2 FLUOROPHENYL] 1 CYCLOHEXYL 5 BENZIMIDAZOLECARBOXYLIC ACID; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; AVI 4065; BILB 1941; BOCEPREVIR; CASTANOSPERMINE 6 BUTYRATE; CILUPREVIR; CPG 10101; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; GS 9190; HCV 759; INTERLEUKIN 10; ISATORIBINE; ISIS 14803; JTK 109; MERIMEPODIB; PEGINTERFERON; PEGINTERFERON ALPHA; PEGYLATED INTERFERON ALPHA; R 7128; RESIQUIMOD; RIBAVIRIN; TARIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE;

ANEMIA; BLOOD TRANSFUSION; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL FEATURE; DEPRESSION; DISEASE COURSE; GENE EXPRESSION PROFILING; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; LIFE CYCLE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RASH; REVIEW; RNA BINDING; RNA INTERFERENCE; RNA SEQUENCE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; VIRUS CULTURE; VIRUS GENOME; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 58849095096     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70020-9     Document Type: Review

References (134)

1. Szabo E., Lotz G., Paska C., Kiss A., and Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathol Oncol Res 9 (2003) 215-221
2. Shepard C.W., Finelli L., Fiore A.E., and Bell B.P. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J 24 (2005) 755-760
3. Frank C., Mohamed M.K., Strickland G.T., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 (2000) 887-891
4. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., and Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006) 529-538
5. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13 (2007) 2436-2441
6. Roberts E.A., and Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 36 5 suppl 1 (2002) S106-S113
7. Terrault N.A. Sexual activity as a risk factor for hepatitis C. Hepatology 36 5 suppl 1 (2002) S99-S105
8. Busch M.P., Glynn S.A., Stramer S.L., et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 45 (2005) 254-264
9. Thorpe L.E., Ouellet L.J., Hershow R., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 155 (2002) 645-653
10. Jain S., Goharkhay N., Saade G., Hankins G.D., and Anderson G.D. Hepatitis C in pregnancy. Am J Perinatol 24 (2007) 251-256
11. McIntyre P.G., Tosh K., and McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev 4 (2006) CD005546.
12. Rooney G., and Gilson R.J. Sexual transmission of hepatitis C virus infection. Sex Transm Infect 74 (1998) 399-404
13. Danta M., Brown D., Bhagani S., et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 21 (2007) 983-991
14. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44 1 suppl (2006) S6-S9
15. Klenerman P., and Kim A. HCV-HIV coinfection: simple messages from a complex disease. PLoS Med 4 (2007) e240
16. Daar E.S., Lynn H., Donfield S., et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 26 (2001) 466-472
17. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
18. Robertson B., Myers G., Howard C., et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 143 (1998) 2493-2503
19. Ogata N., Alter H.J., Miller R.H., and Purcell R.H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 88 (1991) 3392-3396
20. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005) 791-796
21. Delgrange D., Pillez A., Castelain S., et al. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol 88 (2007) 2495-2503
22. Wu G.Y., Konishi M., Walton C.M., Olive D., Hayashi K., and Wu C.H. A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology 128 (2005) 1416-1423
23. Lubin I., Faktorowich Y., Lapidot T., et al. Engraftment and development of human T and B cells in mice after bone marrow transplantation. Science 252 (1991) 427-431
24. Dandri M., Burda M.R., Zuckerman D.M., et al. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol 42 (2005) 54-60
25. Kremsdorf D., and Brezillon N. New animal models for hepatitis C viral infection and pathogenesis studies. World J Gastroenterol 13 (2007) 2427-2435
26. Blackard J.T., Kemmer N., and Sherman K.E. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 44 (2006) 15-22
27. Bartosch B., Vitelli A., Granier C., et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278 (2003) 41624-41630
28. Bartosch B., and Cosset F.L. Cell entry of hepatitis C virus. Virology 348 (2006) 1-12
29. Evans M.J., von Hahn T., Tscherne D.M., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446 (2007) 801-805
30. Bartosch B., Dubuisson J., and Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197 (2003) 633-642
31. Timpe J.M., Stamataki Z., Jennings A., et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47 (2008) 17-24
32. Reynolds G.M., Harris H.J., Jennings A., et al. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 47 (2008) 418-427
33. Rocha-Perugini V., Montpellier C., Delgrange D., et al. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS ONE 3 (2008) e1866
34. Ji H., Fraser C.S., Yu Y., Leary J., and Doudna J.A. Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA. Proc Natl Acad Sci USA 101 (2004) 16990-16995
35. Otto G.A., and Puglisi J.D. The pathway of HCV IRES-mediated translation initiation. Cell 119 (2004) 369-380
36. Penin F., Dubuisson J., Rey F.A., Moradpour D., and Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 39 (2004) 5-19
37. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., and Rice C.M. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci USA 90 (1993) 10583-10587
38. Bartenschlager R., Ahlborn-Laake L., Mous J., and Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 67 (1993) 3835-3844
39. Tomei L., Failla C., Santolini E., De Francesco R., and La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67 (1993) 4017-4026
40. Bartenschlager R., Frese M., and Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63 (2004) 71-180
41. Tanaka Y., Shimoike T., Ishii K., et al. Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5′ untranslated region of the viral genome. Virology 270 (2000) 229-236
42. Kalams S.A., and Walker B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188 (1998) 2199-2204
43. Lauer G.M., Lucas M., Timm J., et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 79 (2005) 12979-12988
44. Lechner F., Wong D.K., Dunbar P.R., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 (2000) 1499-1512
45. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
46. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 36 5 suppl 1 (2002) S21-S29
47. Chuang W.C., Sarkodie F., Brown C.J., et al. Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. J Med Virol 79 (2007) 724-733
48. Fanning L.J. The Irish paradigm on the natural progression of hepatitis C virus infection: an investigation in a homogeneous patient population infected with HCV 1b. Int J Mol Med 9 (2002) 179-184
49. Asselah T., Bieche I., Paradis V., Bedossa P., Vidaud M., and Marcellin P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 27 (2007) 13-27
50. Rustgi V.K. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 42 (2007) 513-521
51. Poynard T., Yuen M.F., Ratziu V., and Lai C.L. Viral hepatitis C. Lancet 362 (2003) 2095-2100
52. Monga H.K., Rodriguez-Barradas M.C., Breaux K., et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33 (2001) 240-247
53. Asselah T., Rubbia-Brandt L., Marcellin P., and Negro F. Steatosis in chronic hepatitis C: why does it really matter?. Gut 55 (2006) 123-130
54. Moucari R., Asselah T., Cazals-Hatem D., et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134 (2008) 416-423
55. Codes L., Asselah T., Cazals-Hatem D., et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 56 (2007) 390-395
56. Davis G.L., Albright J.E., Cook S.F., and Rosenberg D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9 (2003) 331-338
57. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
58. Galossi A., Guarisco R., Bellis L., and Puoti C. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 16 (2007) 65-73
59. Agnello V., and De Rosa F.G. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 40 (2004) 341-352
60. Misiani R., Bellavita P., Fenili D., et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117 (1992) 573-577
61. Pawlotsky J.M., Roudot-Thoraval F., Simmonds P., et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 122 (1995) 169-173
62. Saadoun D., Asselah T., Resche-Rigon M., et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology 43 (2006) 1337-1345
63. Sansonno D., Cornacchiulo V., Iacobelli A.R., Di Stefano R., Lospalluti M., and Dammacco F. Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology 21 (1995) 305-312
64. Johnson R.J., Gretch D.R., Yamabe H., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328 (1993) 465-470
65. Ferri C., La Civita L., Cirafisi C., et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol 19 (1992) 889-895
66. Chevaliez S., and Pawlotsky J.M. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol 13 (2007) 2461-2466
67. Neyts J. Selective inhibitors of hepatitis C virus replication. Antiviral Res 71 (2006) 363-371
68. Carithers Jr. R.L., and Emerson S.S. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 26 3 suppl 1 (1997) 83S-88S
69. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 (1998) 1485-1492
70. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
71. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
72. Schiff E.R. Emerging strategies for pegylated interferon combination therapy. Nat Clin Pract Gastroenterol Hepatol 4 suppl 1 (2007) S17-S21
73. Lindsay K.L., Trepo C., Heintges T., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34 (2001) 395-403
74. Zeuzem S., Feinman S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343 (2000) 1666-1672
75. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
76. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
77. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
78. Poordad F., Reddy K.R., and Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 46 (2008) 78-84
79. Calleri G., Cariti G., Gaiottino F., et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 14 (2007) 116-121
80. De Rosa F.G., Bargiacchi O., Audagnotto S., et al. Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha-2b in injection drug users. Clin Infect Dis 45 (2007) 583-588
81. Asselah T., Bieche I., Narguet S., et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57 (2008) 516-524
82. Berg T., von Wagner M., Nasser S., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 (2006) 1086-1097
83. Sanchez-Tapias J.M., Diago M., Escartin P., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 (2006) 451-460
84. Huang Z., Murray M.G., and Secrist III J.A. Recent development of therapeutics for chronic HCV infection. Antiviral Res 71 (2006) 351-362
85. Gish R.G., Arora S., Reddy K.R., et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 47 (2007) 51-59
86. Reesink H.W., Zeuzem S., Weegink C.J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131 (2006) 997-1002
87. Forestier N., Reesink H.W., Weegink C.J., et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46 (2007) 640-648
88. Lawitz E., Rodriguez-Torres M., Muir A.J., et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 49 (2008) 163-169
89. Sarrazin C., Rouzier R., Wagner F., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132 (2007) 1270-1278
90. Pierra C., Amador A., Benzaria S., et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 49 (2006) 6614-6620
91. Lalezari J., Gane E., Rodrigues-Torres M., et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor, R7128, in combination with PEG IFNα-2a and ribavirin. J Hepatol 48 suppl 2 (2008) S29
92. Pockros P.J., Nelson D., Godofsky E., et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48 (2008) 385-397
93. Tomei L., Altamura S., Bartholomew L., et al. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol 78 (2004) 938-946
94. Villano S., Raible D., Harper D., et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naive patients with chronic hepatitis C virus. J Hepatol 46 suppl 1 (2007) S24
95. Horsmans Y., Berg T., Desager J.P., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42 (2005) 724-731
96. Pockros P.J., Guyader D., Patton H., et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 47 (2007) 174-182
97. McHutchison J.G., Bacon B.R., Gordon S.C., et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46 (2007) 1341-1349
98. Nelson D.R., Lauwers G.Y., Lau J.Y., and Davis G.L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 118 (2000) 655-660
99. Flisiak R., Horban A., Gallay P., et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47 (2008) 817-826
100. Chevalier C., Saulnier A., Benureau Y., et al. Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs. Mol Ther 15 (2007) 1452-1462
101. Cholongitas E., and Papatheodoridis G.V. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther 27 (2008) 866-884
102. McHutchison J.G., Bartenschlager R., Patel K., and Pawlotsky J.M. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 44 (2006) 411-421
103. Pawlotsky J.M., Chevaliez S., and McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132 (2007) 1979-1998
104. McHutchison J.G., Shiffman M.L., Cheung R.C., et al. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther 10 (2005) 635-643
105. Marcellin P., Horsmans Y., Nevens F., et al. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. J Hepatol 47 (2007) 476-483
106. Reiser M., Hinrichsen H., Benhamou Y., et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41 (2005) 832-835
107. Hinrichsen H., Benhamou Y., Wedemeyer H., et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127 (2004) 1347-1355
108. Le Pogam S., Seshaadri A., and Kosaka A. A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1 infected treatment naive patients. Hepatology 46 suppl 1 (2007) 813A
109. Reddy R., Rodrigues-Torres M., Gane E., et al. Antiviral activity pharmacokinetics safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor following multiple ascending oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 46 suppl 1 (2007) 862A-863A
110. Erhardt A., Wedemeyer H., and Benhamou Y. Safety, pharmacokinetics and antiviral effect of BILB1941, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol 46 suppl 1 (2007) S222
111. Cooper C., Lawitz E.J., and Ghali P. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: results from a randomized double blind placebo controlled ascending multiple dose study. Hepatology 46 suppl 1 (2007) 864A
112. Yoshida E., Kunimoto D., Lee S., Sherman M., Heathcote J., and Enns R. Results of a phase II dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C genotype-1 patients. Gastroenterology 130 suppl 2 (2006) A784
113. De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2 (2004) 704-720
114. Meurs E.F., and Breiman A. The interferon inducing pathways and the hepatitis C virus. World J Gastroenterol 13 (2007) 2446-2454
115. Yao N., Reichert P., Taremi S.S., Prosise W.W., and Weber P.C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7 (1999) 1353-1363
116. Lawitz E., Rodriguez-Torres M., Muir A.J., et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 49 (2008) 163-169
117. McHutchison J., Everson G.T., and Gordon S.C. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. J Hepatol 48 suppl 2 (2008) S4
118. Dusheiko G., Hezode C., and Pol S. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: further interim analysis results of the PROVE2 study. J Hepatol 48 suppl 2 (2008) S26
119. Bressanelli S., Tomei L., Roussel A., et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 96 (1999) 13034-13039
120. Carroll S.S., Tomassini J.E., Bosserman M., et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem 278 (2003) 11979-11984
121. Sarisky R.T. Non-nucleoside inhibitors of the HCV polymerase. J Antimicrob Chemother 54 (2004) 14-16
122. Freeman J.A., Heffernan J., Klucher K., et al. Assessment of the pharmacological activity of pegylated recombinant interleukin-29 (PEG-rIL-29) in cynomolgus monkeys. Hepatology 44 suppl 1 (2006) A534
123. Nakagawa M., Sakamoto N., Tanabe Y., et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129 (2005) 1031-1041
124. Watanabe T., Umehara T., and Kohara M. Therapeutic application of RNA interference for hepatitis C virus. Adv Drug Deliv Rev 59 (2007) 1263-1276
125. Gil J., and Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 5 (2000) 107-114
126. Takaoka A., Hayakawa S., Yanai H., et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (2003) 516-523
127. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
128. Lin C., Gates C.A., Rao B.G., et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 280 (2005) 36784-36791
129. Mo H., Lu L., Pilot-Matias T., et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 49 (2005) 4305-4314
130. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70 (2006) 28-38
131. Yi M., Tong X., Skelton A., et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 281 (2006) 8205-8215
132. Lin K., Perni R.B., Kwong A.D., and Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 50 (2006) 1813-1822
133. McCown M.F., Rajyaguru S., Le Pogam S., et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 52 (2008) 1604-1612
134. Papatheodoridis G.V., Manolakopoulos S., Dusheiko G., and Archimandritis A.J. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 8 (2008) 167-178